Fangfang Liu

1.9k total citations
63 papers, 1.4k citations indexed

About

Fangfang Liu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Fangfang Liu has authored 63 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 14 papers in Surgery. Recurrent topics in Fangfang Liu's work include Pancreatic and Hepatic Oncology Research (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Gastrointestinal Tumor Research and Treatment (6 papers). Fangfang Liu is often cited by papers focused on Pancreatic and Hepatic Oncology Research (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Gastrointestinal Tumor Research and Treatment (6 papers). Fangfang Liu collaborates with scholars based in China, United States and Hong Kong. Fangfang Liu's co-authors include Feng Gu, Xinmin Zhang, Zhi Yao, Li Fu, Jing Zhao, Gordon A. Pringle, Yu Fan, Dong Yin, Ronggang Lang and Xiaolong Qian and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Fangfang Liu

58 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fangfang Liu China 20 617 359 334 212 205 63 1.4k
Yunshan Wang China 19 482 0.8× 478 1.3× 340 1.0× 128 0.6× 246 1.2× 55 1.5k
Shu Cao United States 23 502 0.8× 478 1.3× 181 0.5× 321 1.5× 209 1.0× 114 1.5k
Arezoo Gowhari Shabgah Iran 21 385 0.6× 405 1.1× 547 1.6× 110 0.5× 130 0.6× 44 1.3k
Shi‐Yi Yang Taiwan 22 417 0.7× 522 1.5× 177 0.5× 142 0.7× 133 0.6× 60 1.6k
Shanglong Liu China 23 638 1.0× 589 1.6× 122 0.4× 311 1.5× 204 1.0× 83 1.4k
Xiaoling Gu China 20 353 0.6× 386 1.1× 151 0.5× 117 0.6× 276 1.3× 41 1.2k
Muhan Lü China 21 479 0.8× 819 2.3× 582 1.7× 458 2.2× 224 1.1× 110 2.1k
Hao Chen China 21 281 0.5× 405 1.1× 110 0.3× 278 1.3× 365 1.8× 120 1.4k
Kazuhito Kawabata Japan 18 220 0.4× 453 1.3× 421 1.3× 167 0.8× 427 2.1× 54 1.6k
Shintaro Hirata Japan 29 407 0.7× 407 1.1× 457 1.4× 331 1.6× 483 2.4× 161 2.5k

Countries citing papers authored by Fangfang Liu

Since Specialization
Citations

This map shows the geographic impact of Fangfang Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fangfang Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fangfang Liu more than expected).

Fields of papers citing papers by Fangfang Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fangfang Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fangfang Liu. The network helps show where Fangfang Liu may publish in the future.

Co-authorship network of co-authors of Fangfang Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Fangfang Liu. A scholar is included among the top collaborators of Fangfang Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fangfang Liu. Fangfang Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peng, Jiao, Fangfang Liu, Lijuan Feng, et al.. (2025). Crystallinity engineering of FexO through doping and ligand design for improved oxygen Catalysis in Zinc-Air batteries. Chemical Engineering Journal. 511. 162093–162093. 1 indexed citations
2.
3.
Chen, Shaoqiu, Fangfang Liu, Yuanyuan Fu, et al.. (2024). A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer. Molecular Cancer. 23(1). 247–247. 4 indexed citations
4.
Wang, Hao‐Wei, Fangfang Liu, Xiaoxia Chen, et al.. (2023). Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases. Experimental Hematology and Oncology. 12(1). 56–56. 9 indexed citations
5.
Zhao, Yiming, Hanlin Zhang, Zhizhuang Joe Zhao, et al.. (2023). Efficacy and safety of Oral LL‐37 against the Omicron BA.5.1.3 variant of SARS‐COV‐2: A randomized trial. Journal of Medical Virology. 95(8). e29035–e29035. 6 indexed citations
6.
Wang, Xiaoxiao, Rui Jin, Xiaohe Li, et al.. (2023). Collagen co-localized with macrovesicular steatosis better differentiates fibrosis progression in non-alcoholic fatty liver disease mouse models. Frontiers in Medicine. 10. 1172058–1172058. 6 indexed citations
7.
8.
Liu, Fangfang, et al.. (2022). Comparison Between Percutaneous Endoscopic Gastrostomy and Nasogastric Feeding in 160 Patients with Swallowing Disturbances: A Two-Year Follow-Up Study. Clinical Interventions in Aging. Volume 17. 1803–1810. 1 indexed citations
9.
Yuan, Xun, Fangfang Liu, Wenhui Zhang, et al.. (2021). A nomogram to predict the overall survival of patients with symptomatic extensive-stage small cell lung cancer treated with thoracic radiotherapy. Translational Lung Cancer Research. 10(5). 2163–2171. 8 indexed citations
10.
Fei, Jun, Lin Fu, Ying Li, et al.. (2020). Reduction of lymphocyte count at early stage elevates severity and death risk of COVID-19 patients: a hospital-based case-cohort study. Archives of Medical Science. 19(5). 1303–1313. 25 indexed citations
11.
Tang, Song, Fangfang Liu, Yumin Li, et al.. (2020). Treatment Selection and Survival Outcomes in Locally Advanced Proximal Gastric Cancer: A National Cancer Data Base Analysis. Frontiers in Oncology. 10. 537051–537051. 4 indexed citations
12.
Liu, Hui, Seung Ho Shin, Hanyong Chen, et al.. (2020). CDK12 and PAK2 as novel therapeutic targets for human gastric cancer. Theranostics. 10(14). 6201–6215. 54 indexed citations
13.
Liu, Fangfang, Danhua Shen, Hanlin Wang, et al.. (2019). [Combined application of immunohistochemical markers to identify pathologic subtypes of ampullary carcinoma and its clinical significance].. PubMed. 48(2). 92–97. 1 indexed citations
14.
Liu, Fangfang, Gabriella Grisotti, Ronald R. Salem, et al.. (2018). Clinical impact of underutilization of adjuvant therapy in node positive gastric adenocarcinoma. Journal of Gastrointestinal Oncology. 9(3). 517–526. 3 indexed citations
15.
16.
Cen, Juan, Li Zhang, Fangfang Liu, Feng Zhang, & Bian‐Sheng Ji. (2016). Long‐Term Alteration of Reactive Oxygen Species Led to Multidrug Resistance in MCF‐7 Cells. Oxidative Medicine and Cellular Longevity. 2016(1). 7053451–7053451. 36 indexed citations
17.
Zang, Hong, Fangfang Liu, Hongling Liu, et al.. (2016). Incidence, risk factors and outcomes of acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF) of underlying cirrhosis. Hepatology International. 10(5). 807–818. 23 indexed citations
18.
19.
Liu, Fangfang, Danhua Shen, Xiaoping Kang, Chunfang Zhang, & Qiujing Song. (2015). New tumour antigen PLAC1/CP1, a potentially useful prognostic marker and immunotherapy target for gastric adenocarcinoma. Journal of Clinical Pathology. 68(11). 913–916. 22 indexed citations
20.
Li, Weidong, Fangfang Liu, Ting Lei, et al.. (2010). The clinicopathological significance of CD44+/CD24−/low and CD24+ tumor cells in invasive micropapillary carcinoma of the breast. Pathology - Research and Practice. 206(12). 828–834. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yunshan Wang Breakdown of academic impact, for papers by Shu Cao Breakdown of academic impact, for papers by Arezoo Gowhari Shabgah Breakdown of academic impact, for papers by Shi‐Yi Yang Breakdown of academic impact, for papers by Shanglong Liu Breakdown of academic impact, for papers by Xiaoling Gu Breakdown of academic impact, for papers by Muhan Lü Breakdown of academic impact, for papers by Hao Chen Breakdown of academic impact, for papers by Kazuhito Kawabata Breakdown of academic impact, for papers by Shintaro Hirata
Rankless by CCL
2026